Publication of Preclinical IL13-PE38 Data Shows Potential of Neopharm Agent Against Glioblastoma Tumors
(Business Wire)NeoPharm, Inc. announced today publication of data on its product IL13-PE38, a chimeric protein composed of human interleukin-13 and a truncated form of Pseudomonas exotoxin. In an experimental, preclinical tumor study, recently published in International Journal of Cancer, IL13-PE38 evidenced significant regression of glioblastoma tumors when injected into such tumors.- Apr 11 7:01 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/bw/010411/0049.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines